PPMI – GOALS 2019 Ken Marek PPMI Annual Meeting May 3, 2018

Slides:



Advertisements
Similar presentations
The Veterans Affairs Central Biorepository and MVP Highlights Mary T
Advertisements

Registries, Databases & Clinical Networks David J Burn Newcastle University.
PRoBaND Parkinson’s Repository of Biosamples and Networked Datasets History Hypotheses Overview Linkage to other studies Funded by Parkinson’s UK Dr Donald.
Tracking the East Midlands contribution to PD-PROBAND Nin Bajaj Clinical Director NPF International Centre of Excellence in PD, East Midlands Trent CLRN.
Virginia Rodriguez Funes, MD, FACS El Salvador. Background  The Latin American population it is now the largest single ethnic group in the United States,
Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April
Pregnancy Outcome Prediction Study University Department of Obstetrics and Gynaecology; PI – Professor Gordon CS Smith BACKGROUND The current pattern of.
Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.
Aging Cognition Evaluation A Unique Opportunity in understanding age related disorders.
SYNOPSIS OF THE PROTOCOL Title: Pregnancy Associated Breast Cancer (PABC); Prospective Data Registry in Saudi Arabia Sponsor: Oncology Department, King.
FTD Family Members Study & Post Mortem Study Alyson Negreira MGH Frontotemporal Disorders Unit.
Zuo-Feng Zhang, MD, PhD Epi242, Prospective:  Cohort Studies: Observational studies  Intervention Studies, Clinical Trials  Nested Case-Control.
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar.
Anticipated FY2016 Appropriations Agency$ Million NIH200 Cancer70 Cohort130 FDA10 Office of the Natl Coord. for Health IT (ONC) 5 TOTAL215 Mission: To.
Home More Information about I-SPY 2 Participating Cancer Centers Peer Support for I-SPY 2 Participants More Information About Breast Cancer I-SPY 2 Breast.
New Oslo PSC biobank.  Broad consent – covers all clinical and research biobanking  Integrated storage of clinical data and biological material  DNA,
PZP: A novel biomarker for early Alzheimer’s disease ? Diana A.T. Nijholt Department of Neurology Laboratory for Clinical and Cancer Proteomics
THE MURDOCK Study: A Rich Data Resource for Biomarker Discovery and Validation Brian D. Bennett 1, Jessica D. Tenenbaum 1, Victoria Christian 1, Melissa.
Biomarkers: types ? Genome DNA Epigenome Genomic Biomarkers
Cancers of the Digestive System November 19, 2007 NCDD Meeting Chair: John M. Carethers, MD Vice Chair: Robert Sandler, MD, MPH.
Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Translation of Human-Induced Pluripotent Stem Cells:
European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.
New research areas in personalised medicines
Myotonic Dystrophy Research: What’s Next
Biomarkers.
Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease  Mirjana Babić.
José L Molinuevo, Craig Ritchie, Miia Kivipelto
OPN -443C>T Genetic Polymorphism and Tumor OPN Expression are Associated with the Risk and Clinical Features of Papillary Thyroid Cancer in a Chinese Cohort.
Dementia Research and Enterprise at Liverpool John Moores University
NYSDOH AIDS Institute Quality of Care Program eHIVQUAL
Karin Wirdefeldt, Daniela Berg
Neural.
Table 2. Data Sharing for (Reporting Period)
Volume 2, Issue 1, Pages (January 2016)
Imaging AD Progression Amyloid Imaging Agents.
THE PARKINSON’S PROGRESSION MARKERS INITIATIVE
Parkinson’s Progression Markers initiative
Wearables and Digital Sensor Technology
Knowledge l Action l Impact
[Presenter’s Name] [title] [Institution’s name]
PPMI in the Medical Literature
Parkinson’s progression markers initiative
From the Indianapolis – Ibadan Dementia Research Project.
ppmi EPIgenetics Andy Singleton and Dena Hernandez
PPMI 2018 ANNUAL INVESTIGATORS MEETING May 2-3
ppmi genetics Andy Singleton Laboratory of Neurogenetics, NIA, NIH
PPMI Beyond 2018.
Participation in clinical trials
Repositories Lunch Meeting, Day 1
Phenoconversion in PPMI
RNA-SEQ IN PPMI Whole-Blood samples
Genetic Information Nondiscrimination Act (GINA)
José L Molinuevo, Craig Ritchie, Miia Kivipelto
National Institute of Mental Health and Neurosciences
Does Multilingualism Protect Against Alzheimer’s Disease
The EMPIR NeuroMET project
Updates in the Management of Parkinson's Disease Psychosis
Volume 25, Issue 3, Pages (March 2017)
Argentina Arg-ADNI Ezequiel Surace, PhD.
DAT Imaging in a cohort of p.A53T SNCA PD patients versus typical PD
2017 Parkinson Disease.
Gait Sub study Anat Mirelman PhD.
Figure 3 Enrichment strategies for clinical trials
*****For more information, please call*****
Schematic overview of the immuno‐infrared‐sensor, the assay read‐out, and BioFINDER and ESTHER study design Schematic overview of the immuno‐infrared‐sensor,
ADNI 3 UPDATE MICHAEL WEINER.
SYNOPSIS OF THE PROTOCOL
Alzheimer's Prevention Research and
[Presenter’s Name] [title] [Institution’s name]
Presentation transcript:

PPMI – GOALS 2019 Ken Marek PPMI Annual Meeting May 3, 2018 New York, NY

ASSESSMENTS/ CLINICAL DATA COLLECTION Shared Data and Biosamples PPMI study details: Synopsis ASSESSMENTS/ CLINICAL DATA COLLECTION Shared Data and Biosamples STUDY POPULATION BIOLOGIC COLLECTION 423 de novo PD subjects (newly diagnosed and unmedicated) 196 age-and gender- matched healthy controls 64 SWEDD subjects 67 individuals with prodromal PD (hyposmic, RBD) 550 LRRK2 or GBA (PD manifest and non- manifesting family members) 50 Synuclein (PD manifest and non-manifesting family members) Subjects followed for 5 to 13 years Motor assessments Neuropsychiatric/neurob ehavioral testing Autonomic, olfaction, sleep DaTSCAN, AV133, Amyloid, DTI/RS MRI Sensor Data DNA, RNA Serum, whole blood and plasma collected at each visit; urine annually CSF collected at baseline, 6mo 12 mo and then annually IPSC in subset Samples aliquotted and stored in central biorepository Post mortem tissue > 1,700,000 Data downloads > 100 Sample requests via BRC Ancillary study development

DATA CLINICAL IMAGING BIOLOGICS GENETICS WEARABLES DNA – METHYLATION RNA SEQ OMICS

Meeting Goals - Review study Success/Challenges Continued outstanding retention Continued compliance clinical, imaging, biofluid data Add to robust biofluid biorepository Report on longitudinal analysis of progression data PD subsets, prediction of progression Integrate data sets Imaging, Genetics, Wearables Develop tools for Prodromal assessments – phenoconversion, pre-motor progression Pathology core Long-term PPMI follow-up – FOUND Wearable/sensor technology How can PPMI inform clinical trials

Goals for PPMI – Think BIGGER Can we assess a Prodromal/Preventive Cohort How to genotype thousands and PD patients and potential at-risk subjects How to develop biofluid biomarkers that inform disease progression – AMP How to assess imaging tools focused on disease pathology How to use sensor technology to better assess study subjects How to take advantage of onset of disease milestones – cognition, gait, dyskinesia How can PPMI utilize Fox Insight